RU2558821C2 - ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 - Google Patents
ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 Download PDFInfo
- Publication number
- RU2558821C2 RU2558821C2 RU2012124985/15A RU2012124985A RU2558821C2 RU 2558821 C2 RU2558821 C2 RU 2558821C2 RU 2012124985/15 A RU2012124985/15 A RU 2012124985/15A RU 2012124985 A RU2012124985 A RU 2012124985A RU 2558821 C2 RU2558821 C2 RU 2558821C2
- Authority
- RU
- Russia
- Prior art keywords
- solution
- igf
- buffer
- pharmaceutical composition
- concentration
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract description 33
- 229940079593 drug Drugs 0.000 title abstract description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 80
- 239000004475 Arginine Substances 0.000 claims abstract description 66
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 66
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000011780 sodium chloride Substances 0.000 claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
- 239000003755 preservative agent Substances 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 25
- 230000002335 preservative effect Effects 0.000 claims abstract description 24
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 13
- 239000008181 tonicity modifier Substances 0.000 claims abstract description 13
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 199
- 238000002360 preparation method Methods 0.000 claims description 97
- 239000000872 buffer Substances 0.000 claims description 88
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 37
- 230000002776 aggregation Effects 0.000 claims description 36
- 238000004220 aggregation Methods 0.000 claims description 36
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 34
- 229940044519 poloxamer 188 Drugs 0.000 claims description 30
- 229920001993 poloxamer 188 Polymers 0.000 claims description 30
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 30
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 29
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 29
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 29
- 229940068977 polysorbate 20 Drugs 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 238000001914 filtration Methods 0.000 claims description 23
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 12
- 239000002033 PVDF binder Substances 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- 229940088679 drug related substance Drugs 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 239000011550 stock solution Substances 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 8
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 94
- 102000018997 Growth Hormone Human genes 0.000 abstract description 80
- 108010051696 Growth Hormone Proteins 0.000 abstract description 80
- 239000000122 growth hormone Substances 0.000 abstract description 79
- 239000007979 citrate buffer Substances 0.000 abstract description 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 9
- 102000013275 Somatomedins Human genes 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 128
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 120
- 229960003121 arginine Drugs 0.000 description 62
- 102000002265 Human Growth Hormone Human genes 0.000 description 59
- 108010000521 Human Growth Hormone Proteins 0.000 description 59
- 239000000854 Human Growth Hormone Substances 0.000 description 58
- 235000014304 histidine Nutrition 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 41
- 239000013049 sediment Substances 0.000 description 21
- 229940023383 increlex Drugs 0.000 description 19
- 108010000594 mecasermin Proteins 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 16
- 229940063149 nutropin Drugs 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 238000011026 diafiltration Methods 0.000 description 10
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 10
- 239000004695 Polyether sulfone Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229920006393 polyether sulfone Polymers 0.000 description 9
- -1 arginine ion Chemical class 0.000 description 8
- 102000044162 human IGF1 Human genes 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000009295 crossflow filtration Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012905 visible particle Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 2
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 229940126523 co-drug Drugs 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000065 osmolyte Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- SGJSPXDVZJIWEO-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)CC(O)(C(O)=O)CC(O)=O SGJSPXDVZJIWEO-WCCKRBBISA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- SNEIUMQYRCDYCH-LURJTMIESA-N N(alpha)-acetyl-L-arginine Chemical compound CC(=O)N[C@H](C(O)=O)CCCNC(N)=N SNEIUMQYRCDYCH-LURJTMIESA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 108700031632 somatrem Proteins 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26185909P | 2009-11-17 | 2009-11-17 | |
| US61/261,859 | 2009-11-17 | ||
| PCT/EP2010/006996 WO2011060922A1 (en) | 2009-11-17 | 2010-11-17 | Formulation for hgh and rhigf-1 combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012124985A RU2012124985A (ru) | 2013-12-27 |
| RU2558821C2 true RU2558821C2 (ru) | 2015-08-10 |
Family
ID=43661042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012124985/15A RU2558821C2 (ru) | 2009-11-17 | 2010-11-17 | ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 |
Country Status (14)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158582B2 (en) | 2005-06-02 | 2012-04-17 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-1 deficiency |
| WO2013014196A1 (en) * | 2011-07-25 | 2013-01-31 | Sandoz Ag | Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| ES2964713T3 (es) * | 2014-10-23 | 2024-04-09 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| WO2016115561A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Formulations and screening of biological therapeutic agents |
| EP3257524B1 (en) * | 2015-02-11 | 2020-08-26 | Gmax Biopharm LLC | Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein |
| ES2962373T3 (es) * | 2016-04-13 | 2024-03-18 | Medimmune Llc | Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas |
| WO2018034867A1 (en) * | 2016-08-15 | 2018-02-22 | The University Of North Carolina At Chapel Hill | Tardigrade disordered proteins as protein stabilizers |
| JP7275027B2 (ja) | 2016-10-06 | 2023-05-17 | アムジェン インコーポレイテッド | 粘度低下タンパク質医薬製剤 |
| US10953074B2 (en) * | 2017-01-08 | 2021-03-23 | Richard D. Lippman | Composition and method for improving sensorineural hearing |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| EP3681602B1 (en) | 2017-09-11 | 2026-04-15 | Oak Hill Bio Limited | Compositions for reducing the incidence of bpd |
| CA3176341A1 (en) * | 2020-04-22 | 2021-10-28 | Zyon AYNI | Pharmaceutical compositions and anti-viral uses thereof |
| KR20230113287A (ko) * | 2020-10-19 | 2023-07-28 | 오크 힐 바이오 리미티드 | 신생아에 사용하기에 적합한 조성물 |
| IL305132A (en) * | 2021-02-12 | 2023-10-01 | Neuren Pharmaceuticals Ltd | Preparations for the treatment of the Prader-Willi phenomenon |
| MX2024006318A (es) * | 2021-11-26 | 2024-08-14 | Genexine Inc | Formulacion para administracion de alta concentracion de proteina de fusion de hormona del crecimiento. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1369125A1 (en) * | 1996-05-03 | 2003-12-10 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US6767892B1 (en) * | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
| US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5681814A (en) * | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
| DK0955062T3 (da) * | 1992-07-31 | 2007-09-17 | Genentech Inc | Vandig formulering indeholdende humant væksthormon |
| JPH10511964A (ja) * | 1995-01-13 | 1998-11-17 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤 |
| JP2001522813A (ja) * | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | 新規のｉｇｆ−ｉ組成物およびその使用 |
| CN1360506A (zh) * | 1999-07-12 | 2002-07-24 | 格兰迪斯生物技术有限公司 | 生长激素配方 |
| CZ305123B6 (cs) * | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
| CA2476934C (en) * | 2002-02-27 | 2009-06-16 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| AU2003249992A1 (en) * | 2002-07-09 | 2004-01-23 | Sandoz Ag | Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| US8158582B2 (en) * | 2005-06-02 | 2012-04-17 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-1 deficiency |
| US20070135343A1 (en) * | 2005-11-01 | 2007-06-14 | Wyeth | Sodium chloride solution for drug reconstitution or dilution |
| LT2049148T (lt) * | 2006-07-06 | 2016-11-25 | Daewoong Co., Ltd. | Žmogaus augimo hormono skysta stabili kompozicija |
| CN102089319B (zh) * | 2008-05-08 | 2013-11-13 | 味之素株式会社 | 蛋白质的重折叠方法 |
-
2010
- 2010-11-17 RU RU2012124985/15A patent/RU2558821C2/ru not_active IP Right Cessation
- 2010-11-17 CA CA2780554A patent/CA2780554C/en not_active Expired - Fee Related
- 2010-11-17 AU AU2010321225A patent/AU2010321225B2/en not_active Ceased
- 2010-11-17 KR KR1020127015526A patent/KR101614983B1/ko not_active Expired - Fee Related
- 2010-11-17 ES ES10784450.8T patent/ES2532007T3/es active Active
- 2010-11-17 JP JP2012539223A patent/JP6084036B2/ja not_active Expired - Fee Related
- 2010-11-17 IN IN2861DEN2012 patent/IN2012DN02861A/en unknown
- 2010-11-17 WO PCT/EP2010/006996 patent/WO2011060922A1/en not_active Ceased
- 2010-11-17 US US13/513,858 patent/US20120270782A1/en not_active Abandoned
- 2010-11-17 EP EP10784450.8A patent/EP2501367B1/en not_active Not-in-force
- 2010-11-17 MX MX2012005195A patent/MX2012005195A/es active IP Right Grant
- 2010-11-17 CN CN201080052050.4A patent/CN102665691B/zh not_active Expired - Fee Related
- 2010-11-17 UA UAA201207340A patent/UA108994C2/uk unknown
- 2010-11-17 BR BR112012011539A patent/BR112012011539A8/pt not_active Application Discontinuation
-
2015
- 2015-10-30 JP JP2015215192A patent/JP6143827B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-30 US US15/281,361 patent/US20170143834A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1369125A1 (en) * | 1996-05-03 | 2003-12-10 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US6767892B1 (en) * | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102665691A (zh) | 2012-09-12 |
| UA108994C2 (uk) | 2015-07-10 |
| IN2012DN02861A (cg-RX-API-DMAC10.html) | 2015-07-24 |
| US20120270782A1 (en) | 2012-10-25 |
| BR112012011539A2 (pt) | 2016-06-28 |
| CA2780554C (en) | 2017-08-15 |
| HK1175711A1 (en) | 2013-07-12 |
| KR101614983B1 (ko) | 2016-04-22 |
| US20170143834A1 (en) | 2017-05-25 |
| JP2016020395A (ja) | 2016-02-04 |
| MX2012005195A (es) | 2012-06-12 |
| EP2501367B1 (en) | 2015-01-21 |
| JP6084036B2 (ja) | 2017-02-22 |
| EP2501367A1 (en) | 2012-09-26 |
| CA2780554A1 (en) | 2011-05-26 |
| JP2013510893A (ja) | 2013-03-28 |
| CN102665691B (zh) | 2015-05-27 |
| KR20120104251A (ko) | 2012-09-20 |
| AU2010321225B2 (en) | 2015-12-03 |
| WO2011060922A1 (en) | 2011-05-26 |
| JP6143827B2 (ja) | 2017-06-07 |
| AU2010321225A1 (en) | 2012-06-07 |
| BR112012011539A8 (pt) | 2017-12-26 |
| ES2532007T3 (es) | 2015-03-23 |
| RU2012124985A (ru) | 2013-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2501367B1 (en) | Formulation for HGH and RHIGF-1 combination | |
| RU2467762C2 (ru) | Составы паратиреоидного гормона и их применение | |
| EP0760677B1 (en) | A pharmaceutical preparation comprising glucagon | |
| US12576025B2 (en) | Pharmaceutical parenteral composition of dual GLP1/2 agonist | |
| JP7738046B2 (ja) | 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 | |
| EP3434283A1 (en) | Medicinal composition comprising peg anti-human ngf antibody fab' fragment | |
| AU2013368990B2 (en) | Pharmaceutical composition | |
| US10052361B2 (en) | Liquid pharmaceutical composition of conjugated erythropoietin | |
| RU2815643C2 (ru) | Фармацевтическая парентеральная композиция двойного агониста glp1/2 | |
| RU2828220C2 (ru) | Фармацевтическая парентеральная композиция двойного агониста glp1/2 | |
| HK1175711B (en) | Formulation for hgh and rhigf-1 combination | |
| US20240101659A1 (en) | Stable therapeutic protein formulation and methods of making the same | |
| TW202320839A (zh) | hGH融合蛋白的高濃度給藥劑型 | |
| HK40111706A (en) | High concentration administration formulation of hgh fusion protein | |
| WO2025141129A1 (en) | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses | |
| US20240366757A1 (en) | Formulations of immune check point inhibitors or like | |
| EP3747428A1 (en) | Stable melphalan liquid injectable formulations | |
| HK1079428A (en) | Acidic insulin preparations with improved stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201118 |